ALLO analyst estimates
Allogene Therapeutics (ALLO) analyst ratings, the average price target and its range, and every firm's latest call.
ALLO analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Apr 14, 2026 | Robert W. Baird | Allogene Therapeutics price target raised to $9 from $7 at Baird | $9.00 |
| Apr 14, 2026 | Bernstein | Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein | $3.85 |
| May 16, 2024 | H.C. Wainwright | Allogene (ALLO) PT Lowered to $9 at H.C. Wainwright | $9.00 |
| May 14, 2024 | B.Riley Financial | Allogene (ALLO) PT Lowered to $7 at B.Riley | $7.00 |
| Jun 13, 2022 | Robert W. Baird | Allogene Therapeutics (ALLO) Stock Price: $11 Target From Baird | $11.00 |
| Jan 3, 2022 | Guggenheim | Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim | $35.00 |
| Dec 3, 2021 | Canaccord Genuity | Allogene Therapeutics clinical hold could be lifted shortly, says Canaccord | $55.00 |
| Oct 8, 2021 | Jefferies | Allogene (ALLO) PT Lowered to $30 at Jefferies | $30.00 |
| Oct 8, 2021 | Oppenheimer | Allogene Therapeutics price target lowered to $40 from $44 at Oppenheimer | $40.00 |
| Oct 8, 2021 | Bank of America Securities | Allogene (ALLO) PT Lowered to $32 at BofA Securities | $32.00 |
| Oct 8, 2021 | Roth Capital | Allogene Therapeutics price target lowered to $35 from $60 at Roth Capital | $35.00 |
| Sep 23, 2021 | Raymond James | Allogene Therapeutics upgraded to Outperform from Market Perform at Raymond James | $36.00 |
- 10 firms rate ALLO: 7 buy, 3 hold, 0 sell.
Updated 2026-11-02 17:52 UTC